Lenvatinib
别名: E7080
中文名称:乐伐替尼,仑伐替尼
目录号:S1164 Purity: 99.97%
Lenvatinib是一种多靶点抑制剂,无细胞试验中,作用于VEGFR2(KDR)/VEGFR3(Flt-4)最有效,IC50为4 nM/5.2 nM,对VEGFR1/Flt-1作用效果稍弱,作用于VEGFR2/3比作用于FGFR1, PDGFRα/β选择性高10倍左右。Lenvatinib (E7080) 也是FGFR1-4、PDGFR、Kit (c-Kit)和RET (c-RET)的抑制剂,并具有强效的抗肿瘤活性。Phase 3。
CAS: 417716-92-8
客户使用Selleck的Lenvatinib发表文献121篇
- Signal Transduct Target Ther, 2024 9(1):249
- Gastroenterology, 2023 S0016-5085(23)00114-2
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Nature, 2021 595(7869):730-734
- Cancer Cell, 2021 S1535-6108(21)00659-0
- J Hematol Oncol, 2020 13(1):11
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Nat Commun, 2024 15(1):1754
- Cell Rep Med, 2024 S2666-3791(24)00201-5
- Redox Biol, 2024 75:103270
- Cell Rep, 2024 43(10):114812
- Cell Mol Life Sci, 2024 81(1):238
- Phytomedicine, 2024 10.1016/j.phymed.2023.155091
- Elife, 2024 13RP95427
- Biomed Pharmacother, 2024 180:117533
- Biochem Pharmacol, 2024 226:116321
- Heliyon, 2024 10(14):e34484
- PLoS One, 2024 19(5):e0299522
- Oncol Lett, 2024 28(4):483
- J Gastrointest Oncol, 2024 15(4):1674-1685
- Discov Oncol, 2024 15(1):709
- Nat Commun, 2023 14(1):6699
- Mol Cell, 2023 83(5):803-818.e8
- Pharmacol Res, 2023 192:106789
- Cell Death Dis, 2023 14(8):515
- Biomed Pharmacother, 2023 164:115002
- Front Immunol, 2023 14:1212577
- Cell Death Discov, 2023 10.1038/s41420-023-01664-y
- Biochem Pharmacol, 2023 214:115681
- Cancer Sci, 2023 114(4):1284-1296
- Cancer Sci, 2023 114(4):1651-1662
- Biochem Pharmacol, 2023 217:115812
- Biomolecules, 2023 10.3390/biom13111647
- Biomedicines, 2023 11(1)112
- J Hepatocell Carcinoma, 2023 10:697-712
- J Hepatocell Carcinoma, 2023 10:483-495
- Cancer Med, 2023 12(15):16416-16430
- Front Med (Lausanne), 2023 10:1095344
- Acta Biochim Biophys Sin -Shanghai), 2023 55(9):1479-1486
- Acta Biochim Biophys Sin (Shanghai), 2023 55(4):661-671
- PeerJ, 2023 11:e14610
- Biochem Biophys Rep, 2023 10.1016/j.bbrep.2023.101566
- Cell Rep Methods, 2023 3(10):100599
- Discov Oncol, 2023 14(1):26
- Nat Commun, 2022 13(1):7113
- Cancer Res, 2022 82(20):3845-3857
- Cancer Res, 2022 canres.2934.2021
- Clin Transl Med, 2022 12(1):e662
- Int J Biol Sci, 2022 18(11):4357-4371
- Cell Death Dis, 2022 13(4):351
- Cell Rep, 2022 39(3):110712
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-01021-2
- JCI Insight, 2022 7(22e158060)
- Front Immunol, 2022 13:990571
- Cell Death Discov, 2022 8(1):177
- Cells, 2022 11(9)1448
- Cancer Sci, 2022 113(9):3193-3210
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:942341
- Sci Rep, 2022 12(1):8007
- Sci Rep, 2022 12(1):12546
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Arch Biochem Biophys, 2022 727:109345
- BMC Cancer, 2022 22(1):1193
- Doctoral Thesis, The University of Western Australia, 2022 10.26182/6xv2-r576
- Hepatology, 2021 10.1002/hep.31921
- Cancer Lett, 2021 519:46-62
- Pharmacol Res, 2021 S1043-6618(21)00413-8
- JCI Insight, 2021 6(15)140364
- Cell Oncol (Dordr), 2021 10.1007/s13402-021-00605-0
- Food Funct, 2021 10.1039/d0fo02270e
- J Clin Endocrinol Metab, 2021 dgab552
- J Clin Endocrinol Metab, 2021 dgab020
- Mol Cancer Ther, 2021 20(11):2198-2206
- Cancers (Basel), 2021 13(11)2539
- Cancers (Basel), 2021 13(14)3487
- Front Oncol, 2021 11:796839
- Molecules, 2021 26(16)4949
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Endocr Relat Cancer, 2021 28(5):311-324
- Biomed Res Int, 2021 2021:6613439
- Biochem Biophys Res Commun, 2021 553:58-64
- In Vivo, 2021 35(2):721-729
- WESTERN SYDNEY UNIVERSITY, 2021
- Liver Cancer, 2020
- Cancers (Basel), 2020 12(3)
- Cell Signal, 2020 70:109573
- Dis Model Mech, 2020 dmm.047779
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Onco Targets Ther, 2020 13:11183-11192
- Onco Targets Ther, 2020 13:7213-7227
- Eur Rev Med Pharmacol Sci, 2020 24(6):2802-2810
- ACS Appl Mater Interfaces, 2019 101021/acsami9b20178
- Cell Death Dis, 2019 10(10):784
- Cell Rep, 2019 28(9):2331-2344
- Int J Cancer, 2019 145(7):1991-2001
- Oncotarget, 2019 10(66):7058-7070
- Int J Endocrinol, 2019 2019:5031696
- Animal Model Exp Med, 2019 2(4):259-268
- Animal Model Exp Med, 2019 2(3):178-184
- Clin Cancer Res, 2018 10.1158/1078-0432
- Oncotarget, 2018
- Biochem Biophys Res Commun, 2018 504(4):878-884
- Clin Cancer Res, 2017 15;23(16):4885-4896
- Arch Toxicol, 2017 91(8):2921-2938
- Mol Cancer Ther, 2017 16(10-:2130-2143
- Oncotarget, 2017 8(43):73766-73773
- Sci Rep, 2017 7(1-:5519
- Exp Ther Med, 2017 14(4):3768-3773
- Mol Cancer Ther, 2016 15(10):2521-2529
- Environ Toxicol Pharmacol, 2016 46:168-73
- Evid Based Complement Alternat Med, 2016 2016:3635209
- Clin Cancer Res, 2015 21(7):1652-64
- Oncotarget, 2015
- Neoplasia, 2014 16(11):972-81
- Asian Pac J Cancer Prev, 2014 5(7):3113-21
- Chin J Cancer Res, 2013 25(5):572-84
- PLoS One, 2013 8(5):e64369
化学信息&溶解度
分子量 | 426.85 |
分子式 | C21H19ClN4O4 |
CAS号 | 417716-92-8 |
Smiles | COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 20 mg/mL ( 46.85 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 10 mg/mL ( 23.42 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 40 mg/mL ( 93.7 mM; Warmed with 50℃ water bath; Ultrasonicated; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:1.05mg/ml
(2.46mM)
操作示例:以 1 mL 工作液为例,取50μL21mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:0.5mg/ml
(1.17mM)
操作示例:以 1 mL 工作液为例,取50μL10mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5% DMSO
95% Corn oil
浓度:0.4mg/ml
(0.94mM)
操作示例:以1 mL工作液为例,取50μL 8mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:2.5mg/ml
(5.86mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。